Clinical Trials Browser

palbociclib × Breast × 30 days × Clear all

NCT07174336 2026-04-17

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Phase 3 Recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT04072952 2026-04-15

mBC

Phase 1/2 Completed

Breast Neoplasms

NCT04920708 2026-04-14

FAIM

Phase 2 Active not recruiting

Breast Neoplasms

NCT05238922 2026-04-14

Study of INCB123667 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting

BreastGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Digestive System Neoplasms

NCT06380751 2026-04-14

EvoPAR-BR01

Phase 3 Recruiting

Advanced Breast Cancer

NCT02465060 2026-04-13

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 2 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT02630693 2026-04-13

Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

Phase 2 Completed

180 enrolled 14 charts

Breast Neoplasms

NCT04553133 2026-04-13

PF-07104091 as a Single Agent and in Combination Therapy

Phase 2 Active not recruiting

BreastGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Small Cell Lung Carcinoma

NCT04767594 2026-04-13

PERFORM

Active not recruiting

Breast Neoplasms

NCT03820830 2026-04-09

POLAR

Phase 3 Active not recruiting

Breast Cancer Recurrent

NCT04841148 2026-04-09

PALAVY

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual

NCT05399329 2026-04-09

Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan

Breast Neoplasms

NCT06188520 2026-04-08

CYCAD-1

Phase 1/2 Recruiting

BreastGynecologic

ER+ HER2- Advanced Breast Cancer

NCT04360941 2026-04-06

PAveMenT

Phase 1 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06065748 2026-04-06

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Phase 3 Recruiting

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT06962969 2026-04-02

A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world Database

Breast Neoplasms

NCT04654208 2026-03-31

SIRI

Breast Neoplasms

NCT07493291 2026-03-30

PALLAS-IRAQ

Active not recruiting

Breast Neoplasms

NCT07492641 2026-03-25

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

Phase 3 Not yet recruiting

HR+/HER2- Breast Cancer

NCT07487129 2026-03-23

Clinical and P

Phase 4 Completed

Breast Neoplasms

NCT07347600 2026-03-20

reaINAVO

Breast Neoplasms